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Rick A. Nishimura, MD, Hartzell V. Schaff, MDD ynamic left ventricular outﬂow obstructionis a major cause of exertional symptoms inpatients with hypertrophic cardiomyopa-
thy. The obstruction is secondary to systolic anterior
motion of the mitral valve abutting against a hyper-
trophied septum, resulting in diastolic dysfunc-
tion, myocardial oxygen supply-demand mismatch,
reduced forward output, and secondary mitral regur-
gitation. Medical treatment directed at decreasing
contractility, improving diastolic ﬁlling, and slowing
heart rate can be successful in reducing symptoms
in many patients. However, there is a subset of
patients who remain severely symptomatic, despite
optimal medical therapy.
Although surgical resection of the septal hyper-
trophy has been an accepted treatment for these
severely symptomatic patients for >5 decades,
techniques have evolved and become highly reﬁned.
Most experienced surgeons favor wider (“extended”)
resection of septal muscle (1,2) rather than resection
of a narrower portion of muscle in the early reports
of Morrow (3). Other interventions have been utilized
to treat left ventricular outﬂow obstruction, including
dual chamber pacing (4), alcohol septal ablation (5,6),
radiofrequency septal ablation, and, most recently,
implantation of a MitraClip (7). Less invasive and less
demanding procedures appeal to patients and to
many clinicians, especially those who treat obstruc-
tive HCM infrequently, but transaortic septal myec-
tomy has remained the optimal therapy for carefully
selected patients with severely symptomatic hy-
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med with a low operative risk (<1% for isolated myec-
tomy) and minimal complications, with documented
sustained improvement in symptoms. These patients,
who were severely limited before the operation, are
generally able to return to a full active lifestyle.
In current practice at centers treating large
numbers of patients, complications of septal myec-
tomy, including septal defects and heart block, are
now seen in <1% of patients undergoing this proce-
dure. The extension of the myectomy distally
has been found to be important for prevention of re-
sidual post-operative obstruction. Special surgical
approaches have also been successful in the treat-
ment of patients with the mid-ventricular and apical
variants of hypertrophic cardiomyopathy (8,9).
The underlying pathophysiologic mechanisms pro-
ducing the systolic gradient are complex: they are
related to septal hypertrophy, but are also due to ab-
normalities of the mitral valve apparatus. Together,
they produce drag forces resulting in systolic anterior
motion of the mitral valve. There are abnormalities of
the mitral valve present in most patients with hyper-
trophic cardiomyopathy, including anterior displace-
ment of the papillarymuscles, anomalous attachments
of the papillary muscles and chordae, and marked
elongation of the leaﬂets themselves. Because mitral
regurgitation is amajor underlying pathophysiological
mechanism in severely symptomatic patients, mitral
valve replacement with a low-proﬁle prosthesis was
initially suggested as a surgical option (10,11). Even
though this procedure relieves both the outﬂow
gradient and mitral regurgitation, it has been avoided
due to the additional adverse consequences of a pros-
thetic valve. To optimize the hemodynamic beneﬁt
of surgery, others have proposed additional mitral
valve repair techniques besides surgical myectomy,
including mobilization of papillary muscles and
extension or plication of the mitral leaﬂets (12–16).
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1698However, experienced surgeons have found that a
complete,well-performedmyectomyaloneissufﬁcient
to obliterate the outﬂow obstruction and relieve the
mitral regurgitation, unless there is an intrinsic pri-
mary abnormality of the mitral valve, such as ruptured
chordae or ﬁbrosed immobile mitral leaﬂets (17).SEE PAGE 1687In this issue of the Journal, Ferrazzi et al. (18)
report on the clinical and hemodynamic results of
a surgical approach in 39 patients with only “mild”
septal hypertrophy, in which cutting thickened sec-
ondary chordae is added to a shallow septal muscle
resection. The results are comparable to the excel-
lent results from other series of patients with
increased septal thickness undergoing conventional
myectomy with residual outﬂow gradients <10 mmHg
and a marked improvement in functional class at
follow-up of nearly 2 years. They demonstrated that
the anterior leaﬂet-annulus ratio was greater and the
tenting area under the mitral valve was smaller than
in patients who had myectomy alone, indicating that
the procedure moved the mitral apparatus more pos-
teriorly, thereby “enlarging the outﬂow tract.” They
conclude that this unique procedure is an important
step forward in the treatment of this subgroup of
patients, whom they consider would otherwise have
received a mitral valve replacement.
Ferrazzi et al. (18) should be congratulated on the
outcome of their surgical experience in this sub-
group of patients. Relief of symptoms is the primary
goal of surgery, which was achieved in all their pa-
tients. Avoidance of a mitral valve replacement is of
great long-term beneﬁt for any patient. However,
the patients were included in this study if the septal
thickness was considered “mild” and <20 mm diam-
eter. In our own practice, isolated septal myectomy
has been effective from both the hemodynamic and
clinical outcome standpoints for patients with septal
thickness as small as 15 mm. The mechanism of a
myectomy is not only to mechanically enlarge the
outﬂow tract, but also to interrupt the abnormal ﬂow
patterns that cause a drag force on the elongated and
abnormally displaced mitral leaﬂets.
Thus, a myectomy in the presence of a thinner
septum will be effective if it is extended distally,where the abnormal ﬂow patterns during systole
begin. It is interesting that Ferrazzi et al. (18)
compared the detailed echocardiographic measure-
ments of mitral valve position from 25 patients with
myectomy alone versus the 39 patients who had sec-
ondary chordal resection. However, there is limited
information on the hemodynamic and clinical out-
come of these 25 patients who underwent myectomy
alone. It is unclear to us how often it is necessary to
add an additional mitral valve procedure to an
adequately performed myectomy to relieve obstruc-
tion and mitral valve regurgitation. In a recent review
of our experience, additional mitral valve procedures
were performed in 2.2% of 1,905 operations, and in-
dications included redundant leaﬂet tissue thought to
contribute to LV outﬂow tract obstruction,minor clefts
in leaﬂets, and iatrogenic injury to chorda during
myectomy or inadvertent injury of themitral valve. No
patients had a mitral valve procedure or valve
replacement because of “inadequate” septal thick-
ness. Dividing secondary chordae at the time of
myectomy may decrease incidence of SAM and post-
operative gradients in selected patients, but it is
important to recognize that the most common cause of
residual outﬂow tract obstruction is failure to carry the
myectomy far enough towards the cardiac apex (19).
For the cardiologist who is caring for these pa-
tients, it is of great importance that there is an
understanding of the outcomes of treatment, partic-
ularly for those patients who remain severely symp-
tomatic despite optimal medical therapy. All would
agree that operations on patients with symptomatic
hypertrophic cardiomyopathy by experienced sur-
geons are truly life-changing interventions that will
restore normal activity to those who were severely
limited before the operation. The ﬁnding of abnor-
malities such as the “relatively thin septum” or
“elongated redundant mitral leaﬂets” should not
deter one from referring the severely symptomatic
patient to centers of excellence with experienced
surgeons for optimal therapy.
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